For patients who are not pregnant, debate continues regarding the optimal CD4 and viral
load at which antiretroviral therapy should be initiated. In pregnancy, however, it is …

Increasing rates of HIV infection in women worldwide, especially among those of
childbearing age, reinforce the importance of understanding the management of HIV in …

The transformation of the human immunodeficiency virus (HIV) epidemic over the last 20
years has been remarkable. With access to appropriate therapies, clinicians can now offer …

The aim of antiretroviral therapy in pregnancy is to deliver a healthy uninfected child to a
healthy mother, without prejudicing the future treatment opportunities of the mother. The use …

The global prevalence of HIV infection in the female population presents a significant
healthcare burden in terms of mother-to-child transmission (MTCT) of the disease. This …

Background The potential for HIV transmission between a pregnant woman and her unborn
child was first recognized in 1982. Since then a complex package of measures to reduce risk …

The HIV global epidemic is having a devastating effect on women of reproductive age;
women aged 15–24 years are 2.5 times more likely to be infected than young men in the …

Human immunodeficiency virus (HIV) infection during pregnancy is a condition that requires
multidisciplinary care. Care must be rendered that is appropriate for both the mother and the …

Zidovudine (AZT)• Approved by FDA and HPB for use in pregnancy• FDA pregnancy
category C• No documented toxic effects in humans, aside from reversible anemia in …

These recommendations update the February 25, 2000 guidelines developed by the Public
Health Service for the use of zidovudine (ZDV) to reduce the risk for perinatal human …